Literature DB >> 21224047

Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis.

Amalia Conti1, Gemma Caballero Rodriguez, Antonella Chiechi, Rosa Maria Dégano Blazquez, Victoria Barbado, Tibor Krènacs, Chiara Novello, Laura Pazzaglia, Irene Quattrini, Licciana Zanella, Piero Picci, Enrique De Alava, Maria Serena Benassi.   

Abstract

Giant cell tumor of bone can be locally aggressive and occasionally can metastasize in the lungs. To identify new markers predictive of aggressive behavior, we analyzed five patients who developed lung metastasis and five who remained disease free for a minimum of 5 years. Using two-dimensional electrophoresis, we detected 28 differentially expressed spots. Fourteen spots were identified using mass spectrometry, including seven up-regulated and seven down-regulated in metastatic samples and classified according to functional categories. We then selected five proteins involved in cell cycle or apoptosis. Thioredoxin peroxidase, allograft inflammatory factor 1, and ubiquitin E2N had more than threefold up-regulation; glutathione peroxidase 1 had 1.9-fold up-regulation; and heat shock protein 27 showed down-regulation in metastatic samples with a very low P value. After validation and analysis of protein levels, evaluation of clinical impact was assessed in a much wider cohort of primary archival specimens. Immunodetection showed a higher frequency of thioredoxin peroxidase, allograft inflammatory factor 1, ubiquitin E2N, and glutathione peroxidase 1 overexpression in primary tumors that developed into lung metastases or that locally relapsed than in the disease-free group, with variable stain intensity and distribution. Kaplan-Meier analysis showed that high expression of glutathione peroxidase 1 was strongly related to local recurrence and metastasis, suggesting that its up-regulation may identify a subset of high-risk patients with giant cell tumor prone to receive diverse clinical management. Copyright Â
© 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21224047      PMCID: PMC3069817          DOI: 10.1016/j.ajpath.2010.11.035

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

Review 1.  New insights into role of microenvironment in multiple myeloma.

Authors:  G Tricot
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 2.  Properties and biological activities of thioredoxins.

Authors:  G Powis; W R Montfort
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001

Review 3.  The dark side of a tumor suppressor: anti-apoptotic p53.

Authors:  R U Jänicke; D Sohn; K Schulze-Osthoff
Journal:  Cell Death Differ       Date:  2008-03-21       Impact factor: 15.828

4.  Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells.

Authors:  V Gouazé; M E Mirault; S Carpentier; R Salvayre; T Levade; N Andrieu-Abadie
Journal:  Mol Pharmacol       Date:  2001-09       Impact factor: 4.436

5.  Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell.

Authors:  Xudong Liu; Bingfang Zeng; Jie Ma; Chunling Wan
Journal:  Cancer Invest       Date:  2009-03       Impact factor: 2.176

Review 6.  Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).

Authors:  Pete Anderson; Lisa Kopp; Nicholas Anderson; Kathleen Cornelius; Cynthia Herzog; Dennis Hughes; Winston Huh
Journal:  Expert Opin Investig Drugs       Date:  2008-11       Impact factor: 6.206

7.  Expression of allograft inflammatory factor-1 and CD68 in haemangioma: implication in the progression of haemangioma.

Authors:  J Jia; Y Bai; K Fu; Z-J Sun; X-M Chen; Y-F Zhao
Journal:  Br J Dermatol       Date:  2008-07-21       Impact factor: 9.302

8.  Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.

Authors:  E Y Lin; A V Nguyen; R G Russell; J W Pollard
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

9.  Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma.

Authors:  Mee-Kyung Cha; Kyung-Hoon Suh; Il-Han Kim
Journal:  J Exp Clin Cancer Res       Date:  2009-06-30

10.  Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues.

Authors:  Jan Vydra; Irena Selicharová; Katerina Smutná; Miloslav Sanda; Eva Matousková; Eva Bursíková; Markéta Prchalová; Zuzana Velenská; David Coufal; Jirí Jirácek
Journal:  BMC Cancer       Date:  2008-04-16       Impact factor: 4.430

View more
  19 in total

Review 1.  Prognosis of local recurrence in giant cell tumour of bone: what can we do?

Authors:  Yifeng He; Ji Zhang; Xiaoyi Ding
Journal:  Radiol Med       Date:  2017-03-07       Impact factor: 3.469

2.  Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin.

Authors:  Peng Yin; Zhuchi Tu; An Yin; Ting Zhao; Sen Yan; Xiangyu Guo; Renbao Chang; Lianhe Zhang; Yan Hong; Xiahe Huang; Junxia Zhou; Yingchun Wang; Shihua Li; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2014-10-24       Impact factor: 6.150

3.  Retrospective analysis of patients with rare-site and metastatic giant cell tumor.

Authors:  Junling Liu; Han Yang; Rui Sun; Zhijun Yang; Zhihua Zhu
Journal:  Chin J Cancer Res       Date:  2013-10       Impact factor: 5.087

4.  p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.

Authors:  Taketo Okubo; Tsuyoshi Saito; Hiroyuki Mitomi; Tatsuya Takagi; Tomoaki Torigoe; Yoshiyuki Suehara; Kazuo Kaneko; Takashi Yao
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

5.  Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Diagnosis and Recurrence Detection of Giant Cell Tumor of Bone.

Authors:  Tetsuya Shinozaki; Kenichi Saito; Tsutomu Kobayashi; Takashi Yanagawa; Kenji Takagishi
Journal:  Open Orthop J       Date:  2012-09-03

6.  Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma.

Authors:  Maria Serena Benassi; Laura Pazzaglia; Chiara Novello; Irene Quattrini; Serena Pollino; Giovanna Magagnoli; Piero Picci; Amalia Conti
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

7.  Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma.

Authors:  Nicole M A White; Daniel W Newsted; Olena Masui; Alexander D Romaschin; K W Michael Siu; George M Yousef
Journal:  Tumour Biol       Date:  2013-10-19

8.  Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges.

Authors:  Wan I Wan-Ibrahim; Vivek A Singh; Onn H Hashim; Puteri S Abdul-Rahman
Journal:  Mol Med       Date:  2015-11-13       Impact factor: 6.354

Review 9.  Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor.

Authors:  Yuhree Kim; Saqib Nizami; Hana Goto; Francis Y Lee
Journal:  Clin Orthop Surg       Date:  2012-05-17

10.  Anti-cancer effect of thiacremonone through down regulation of peroxiredoxin 6.

Authors:  Miran Jo; Hyung-Mun Yun; Kyung-Ran Park; Mi Hee Park; Dong Hun Lee; Seung Hee Cho; Hwan-Soo Yoo; Yong-Moon Lee; Heon Sang Jeong; Youngsoo Kim; Jae Kyung Jung; Bang Yeon Hwang; Mi Kyeong Lee; Nam Doo Kim; Sang Bae Han; Jin Tae Hong
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.